The CD44 glycoprotein is expressed in multiple isoforms on a variety of cell types where it functions as a receptor for hyaluronan-mediated motility. Recently, interest has centered on CD44 heparan sulfate proteoglycan (HSPG) isoforms because of their potential to sequester heparin-binding growth factors and chemokines. Expression of these isoforms on ectodermal cells has recently been shown to regulate limb morphogenesis via presentation of fibroblast growth factor (FGF) 4/FGF 8 while expression on tumor cells was shown to sequester hepatocyte growth factor and promote tumor dissemination. To date, however, CD44 HSPG expression in tissue macrophages and lymphocytes has not been adequately investigated, despite the fact these cells actively synthesize growth factors and chemokines and indirect evidence that monocyte CD44 sequesters macrophage inflammatory protein-1␤. Here we show primary human monocytes rather than lymphocytes express CD44 HSPGs, but only following in vitro differentiation to macrophages or activation with the proinflammatory cytokine interleukin-1␣ or bacterial lipopolysaccharide. Furthermore, we show these isoforms are preferentially modified with heparan rather than chondroitin sulfate, bind the macrophage-derived growth factors FGF-2, vascular endothelial growth factor, and heparin-binding epidermal growth factor with varying affinities (K d 25-330 nM) and in the case of FGF-2, can stimulate productive binding to the high affinity tyrosine kinase FGF receptor 1 (FGFR1). In contrast, we find no evidence for significant binding to C-C chemokines. Last, we confirm by immunofluorescent antibody staining that inflamed synovial membrane macrophages express CD44 HSPGs and that expression is greatest in cells containing high FGF-2 levels. These results suggest a paracrine role for macrophage CD44 HSPG isoforms in the regulation of growth factor action during inflammation.
The human CD44 molecule is a widely expressed cell surface receptor for hyaluronan (HA) 1 that occurs in multiple isoforms generated by differential splicing of up to nine alternative exons (v2-v10) into a single site within the extracellular domain (1) . The common N-terminal ectodomain contains the binding site for hyaluronan within a protein module homologous to the B-domain of cartilage link protein (2, 3) . The variable portion is largely mucin-like and differs in length between isoforms according to the number and nature of spliced exons inserted therein (4) . The pattern of CD44 alternative splicing is highly tissue-specific (1) . For example, cells in most normal tissues express only the standard CD44H isoform and constitutive expression of the alternatively spliced variants is restricted almost exclusively to epithelia or neoplastic cells (5) . In hemopoietic cells and some transformed cell lines, however, alternative splicing of exons including v6 and v9 can be induced by cell activation or by treatment with inflammatory cytokines such as interleukin-1 (IL-1) and TNF␣ (6 -10) . In rodents, the induced lymphocyte isoforms have also been reported to play a role in T-and B-cell effector functions (7) . Potentially, CD44 isoforms could also help regulate leukocyte trafficking into tissues such as the synovial membrane, where CD44 levels on leukocytes are up-regulated by inflammation (11, 12) , and interactions with HA or other ligands appear to be critically important for extravasation (13, 14) .
The precise functions of all the CD44 alternative exons are still not fully clear. However, two general roles have emerged from recent data. First, the insertion of variant exons and their glycosylation can regulate HA-binding, presumably by altering the conformation of the link module (15) or by inducing CD44 oligomerization (16) . Second, individual alternative exons may confer binding sites for novel CD44 ligands, unrelated to HA. For example, the v3 exon uniquely contains a motif SGSG that directs O-glycosylation with heparan and chondroitin sulfates * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. and its inclusion is now known to generate CD44 heparan sulfate proteoglycan (HSPG) forms that are abundant on epithelial cells (17, 18) . One of the main functions associated with HSPGs is the sequestration of heparin-binding growth factors and chemokines. This can increase the half-life of bound growth factor by protecting against proteolytic degradation (19) . Furthermore, in the case of fibroblast growth factors (FGFs), sequestration by free heparin or cell surface HSPGs appears to drive growth factor dimerization and subsequent binding and cross-linking of the high affinity signal-transducing receptors (20, 21) . These same functions may well be shared by CD44 HSPGs. These certainly bind the growth factors FGF-2 and heparin-binding EGF (hbEGF) as first demonstrated using truncated ectodomain constructs in monkey COS cells (18) . In addition, CD44 HSPG isoforms identified in the embryonic mouse apical ectodermal ridge have been shown to bind and present FGF-4 and FGF-8 during limb bud development in embryonic mice (22) and CD44 HSPGs from tumor cells have been shown to present hepatocyte growth factor as a mechanism to increase tumor cell dissemination (23) . To date, however, no quantitative estimates of CD44 HSPG/growth factor binding affinities have been reported.
The expression of CD44 HSPGs by hemopoietic cells has received comparatively little attention, despite the fact activated lymphocytes and particularly macrophages up-regulate CD44 (24) and synthesize many heparin-binding growth factors and chemokines. Furthermore, in one report, leukocytederived CD44 molecules presumed to carry heparan or chondroitin sulfate chains were shown to sequester the heparinbinding chemokine macrophage inhibitory protein (MIP)-1␤ (25) . In the light of such evidence we have investigated the expression of CD44 HSPGs on primary human leukocytes and have characterized their ligand-binding properties. Here we show CD44 HSPG isoforms similar to those of neoplastic epithelial cells are inducible specifically on macrophages, that they constitute intermediate affinity receptors for macrophagederived growth factors FGF-2, VEGF, and hbEGF but not chemokines and that they can present FGF-2 in paracrine fashion to its receptor (FGFR1) on adjacent cells. We further show these CD44 HSPG isoforms are dramatically up-regulated on synovial membrane and subintimal macrophages in inflammatory (rheumatoid) arthritis and co-localize with cells containing cytoplasmic FGF-2. The likely physiological significance of these findings is discussed.
EXPERIMENTAL PROCEDURES
Cytokines, Antibodies, Growth Factors, and Enzymes-Cytokines including IL-1␣, IL-2, TNF␣, interferon-␥, granulocyte macrophagecolony stimulating factor, and the purified, carrier-free chemokines MIP-1␤, MCP-1, and RANTES were obtained from R & D Systems Europe, Abingdon, United Kingdom. The fluorescent chemokine deriv- (26, 27) Purification and Culture of Monocytes and T Lymphocytes-Monocytes and T-cells were purified from blood (ABO group B) donated by healthy human volunteers. As the initial step in both purifications, the peripheral blood mononuclear cell (PBMC) fraction was first isolated by centrifugation through Lymphoprep density gradient media (Nycomed, Norway) using standard methods.
Monocytes were isolated from the PBMC preparations by their selective adherence to plastic tissue culture dishes (1 ϫ 10 6 cells/cm 2 , 0.5 h) in the presence of 10% autologous human serum. Briefly, suspensions of PBMC (2 ϫ 10 8 cells in 25 ml) in RPMI 1640, 10% fresh autologous human serum were incubated in 15-cm tissue culture dishes for 30 min at 37°C followed by successive rinsing of the adherent cells with warmed media to remove contaminating lymphocytes. The monocytes were then detached for immediate analysis or were placed in culture (37°C, 5% CO 2 ) in complete media alone or in the presence of the inflammatory mediators IL-1␣ (1 ng/ml), TNF␣ (100 ng/ml), interferon-␥ (1,000 units/ml), or lipopolysaccharide (0.5 g/ml) or the protein synthesis inhibitor cycloheximide (5 g/ml) for up to 5 days prior to detachment by incubation with PBS, 5 mM EDTA, pH 7.5 (1 h, 5°C). Populations were normally Ͼ80% pure as assessed by immunofluorescent antibody staining with antibodies to the human monocyte specific marker CD14 and FACS analysis (see below).
T-cells were isolated from PBMC by selective removal of B-cells and monocytes using goat anti-human IgG and chromatography on glass bead columns (Cellect TM T-cell enrichment immunocolumns, Biotex Laboratories, Canada). The remaining purified T-cells were induced to proliferate by incubation (2 ϫ 10 6 cells/ml, 24 -120 h) with the mitogenic lectin phytohemagglutinin (5 g/ml, Wellcome) in RPMI 1640, 10% fetal calf serum. Activation was confirmed by measuring (a) the incorporation of ) were incubated (30 min, 5°C) with saturating concentrations (Ͼ10 g/ml IgG) of the appropriate mouse mAbs in PBS, pH 7.5, supplemented with 5% normal human serum, 0.1% sodium azide, followed by washing and reincubation (20 min, 5°C) either with FITC-conjugated or PE-conjugated goat anti-mouse IgG (1/100 dilution).
For double-staining, cells were first indirectly stained with anti-CD44 v3 and fluorescent anti-mouse Ig (either FITC or PE-conjugated as appropriate) in PBS, pH 7.5, supplemented with 5% normal human serum, followed by direct staining (30 min, 5°C) with PE-conjugated CD14 mAb or FITC-conjugated CD25 mAb as appropriate, in PBS supplemented with 10% normal mouse serum. Again, isotype-matched irrelevant mAbs were used to control for background nonspecific staining. Cells were finally fixed in PBS containing 2% (v/v) formaldehyde and stored at 5°C in the dark prior to analysis on a Becton Dickinson (3.7 MBq/ml) as described previously, and washed (3 times) in cold medium to remove unincorporated isotope. In both cases the labeled cells were then extracted into 1.5 ml of Tris-HCl (20 mM), pH 7.5, containing Triton X-100 (1%), NaCl (150 mM), EDTA (1 mM), and the proteinase inhibitors phenylmethanesulfonyl fluoride (0.5 mM), leupeptin (50 g/ml), and iodoacetamide (5 mM). After centrifugation to remove particulate material the resulting supernatants were pre-cleared with 10% (w/v) Pansorbin (Calbiochem) followed by Protein A-Sepharose CL-4B/mouse IgG (1 h, 5°C) prior to incubation with the appropriate specific mAb (10 g/ml) and recovery of the immune complexes on beads of Protein A-Sepharose CL-4B. Finally, immune complexes were washed with TEN buffer (20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA) containing Triton X-100 (0.1%) and subjected to enzymatic deglycosylation or recovered for electrophoresis by boiling with SDS-PAGE sample buffer. For selective cleavage of heparan and chondroitin sulfate, samples were incubated (2 h, 37°C) with 10 milliunits/ml heparinase III (heparan sulfate lyase, EC 4.2.2.8, Seikagaku Corp., Japan) or 100 milliunits/ml chondroitinase ABC (chondroitin ABC lyase, EC 4.2.2.4; Roche Molecular Biochemicals).
SDS-PAGE and Autoradiography-Samples of surface-iodinated monocytes, T-cells, PBMC, or 35 SO 4 metabolically labeled cells were routinely electrophoresed on 12.5% polyacrylamide SDS-PAGE gels followed by autoradiography using Kodak X-Omat X-Ray film.
Reverse Transcriptase-PCR and Northern Blotting-Transcripts of total CD44 and of CD44 v3 HSPG isoforms were detected by reverse transcriptase-polymerase chain reaction (RT-PCR) and Northern blotting using total cellular RNA isolated from cultured human monocytes solubilized with guanidinium isothiocyanate using the method of Chomczynski et al. (30) .
For RT-PCR, oligo(dT)-primed first strand cDNA synthesis was accomplished using the method described in a previous publication from our laboratory (31) . At the end of the reaction, 1-l samples of cDNA from a total volume of 35 l were added without further purification to PCR reaction mixtures (100 l) that contained 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 2 mM MgCl 2 , 250 M deoxyribonucleotide triphosphates, 1 unit of Taq DNA polymerase (Roche Molecular Biochemicals), and the CD44 oligonucleotide primers AMP1Eco (5Ј-CCGGAATTCCCAGTAT-GACACATATTGC-3Ј, 200 nM) and AMP2Eco (5Ј-CCGGAATTCCAAG-ATGATCAGCCATTCTGG-3Ј, 200 nM) located, respectively, 313 nucleotides upstream and 130 nucleotides downstream of the CD44 alternative splice site (32) . The conditions for DNA amplification were 30 cycles at 94°C, 1 min; 55°C, 1 min; 72°C, 1 min, in a Perkin-Elmer DNA thermal cycler. The PCR products were transferred to Hybond N ϩ (Amersham Pharmacia Biotech) and probed (37°C, 6 ϫ SSC) with 32 P end-labeled oligonucleotides complementary to exon v3 (pv3, CAGCC-TGCTGAGATGGTATTTG) or to constitutive exon 4 (P1, TGTACA TCAGTCACAGACCTGCA). Filters were washed at 55°C (6 ϫ SSC) for 5 min prior to autoradiography.
For Northern blotting, samples of total RNA (15 g) were electrophoresed on 1.2% agarose/formaldehyde gels and transferred to charged Nylon membranes (Hybond N ϩ , Amersham Pharmacia Biotech) and hybridized with a full-length CD44H probe (32), radiolabeled with 32 P by random hexamer priming. Blots were washed at high stringency (65°C, 0.2 ϫ SSC) prior to autoradiography.
Construction of Mutant CD44 v3 Isoforms Lacking HS Chains and Transfection of B-lymphoma Namalwa
Cells-Mutant CD44 isoforms lacking heparan sulfate chains were constructed by oligonucleotidedirected mutagenesis of the SGSG motif within the v3 exon in CD44v3,8 -10 and v3-10 cDNAs using a proprietary kit (U-DNA Mutagenesis Kit; Roche Molecular Biochemicals) based on the method of Kunkel (33) . Wild-type CD44v3,8 -10 and v3-10 cDNAs were subcloned into the HindIII/NotI site in pBluescript and ligated to a 45-mer oligonucleotide 5Ј-GACAGACACCTCAGTTTT(gccGGcgCAGGC)ATTGATG-ATGATGAA-3Ј containing five nucleotide substitutions (lowercase) to mutate the sequence coding for the O-glycanation motif SGSG to AGAG (in parentheses) and introduce a diagnostic NaeI restriction site (underlined). Following primed synthesis of the second strand with T4 DNA polymerase, mutated inserts were re-cloned into pRcCMVand used to transfect human Namalwa B-lymphoma cells by electroporation. Stable transfectants were confirmed to lack HS modification as assessed using the HS-specific mAb 10E4 (Seikagaku Corp.) and displayed comparable levels of surface expression to the wild-type equivalents as assessed using the CD44 mAbs F.10.44.2, Hermes-1, and KZ 1 by FACS analysis. Namalwa transfectants expressing wild-type CD44H, CD44v3,8 -10 and v3-10, syndecan-1, -2, and -4 and glypican-1 have been described previously (17) and were cultured in RPMI 1640, 10% fetal calf serum.
Radioligand Binding Assays-For binding assays, MDM were dispensed into 96-well microtiter dishes and incubated (4 h, 5°C) with different concentrations of radioiodinated growth factors and chemokines (FGF-2, VEGF, hbEGF, MCP-1, and MIP-1␤), or fluorescent NBD-labeled RANTES either alone (total binding), or in the presence of a 100-fold molar excess of unlabeled growth factor (nonspecific binding) or 10 g/ml free heparin (non-HSPG-mediated binding) in 50 l of binding buffer (RPMI 1640, 1 mg/ml bovine serum albumin, 0.1% sodium azide), followed by four washes to remove unbound growth factor. The levels of bound and free radioligand in each case were determined by counting samples of the cell pellet and the combined washes, respectively. In the case of the fluorescent chemokine NBD-RANTES, binding was measured by flow cytometry using a Becton-Dickinson FACScan as described above. Equilibrium binding constants were estimated from Scatchard plots (B versus B/F), where B represents specifically bound ligand (total bound minus nonspecifically bound) and F represents free radioligand.
BaF32 Cell Proliferation (Transactivation) Assay-The ability of CD44 HSPGs to act as intermediate affinity FGF receptors and induce signaling via tyrosine kinase FGF receptors was assessed using glutaraldehyde-fixed Namalwa (B-lymphoma cell) transfectants and FGFR1-transfected BaF32 cells in a modification of the proliferation assay described (34, 35) . Proliferation was measured as mitochondrial NADH/NADPH-dependent dehydrogenase activity in a colorimetric assay in which the substrate MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethyoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt) is reduced to a water soluble formazan dye. Briefly, transfectants were fixed with glutaraldehyde (1% (w/v) in PBS, pH 7.5), blocked with glycine (0.1 M in PBS, pH 7.5, 30 min), and suspended in RPMI 1640, 0.5% fetal calf serum. Fixed cells (50 l, 1.5-3 ϫ 10 6 /ml) were then mixed with an equal volume of BaF32 cells (3 ϫ 10 5 /ml) and recombinant FGF-2 (10 nM, final concentration) in the same media in 96-well microtiter plates (final volume 180 l/well) and incubated for 3-5 days at 37°C. At the end of this period, MTS (150 M in water) was added to each well and the plates developed at 37°C for 1 h prior to spectrophotometry on a Bio-Rad enzyme-linked immunosorbent assay plate reader at 595 nm.
Immunoperoxidase and Double Immunofluorescence Staining of Synovial Tissue-Samples of synovial tissue from patients with seropositive rheumatoid arthritis were obtained during routine surgical operations and biopsies performed at the Nuffield Orthopaedic Center, Oxford Radcliffe Trust Hospital, United Kingdom, and snap frozen in liquid nitrogen prior to storage at Ϫ70°C. Cryostat sections (8 mm) were cut onto multiwell slides, dried overnight at room temperature, fixed in acetone for 10 min and then air-dried. Slides were incubated (30 min, 25°C) with appropriate primary mAbs (10 g/ml) followed by peroxidase-conjugated secondary antibodies for 30 min at 25°C. Omission of the primary antibody was used as a negative control. All sections were then counterstained with hematoxylin prior to mounting.
For two-color immunofluorescent antibody staining, tissue sections were treated with primary lineage-specific mAbs (CD3, CD14, VCAM-1, CD163, or vs38) for 30 min at 25°C followed by FITC or Texas Redconjugated goat anti-mouse IgG 1 , IgG 2a , or IgG 2b as appropriate. Sections were counterstained with 4,6-diamidino-2-phenylindole (10 min 25°C) prior to mounting in fluorescent mounting medium (Dako) and viewing under a Zeiss microscope with epifluorescent illumination.
RESULTS

CD44 Isoforms Containing the HS-modified v3 Exon Are
Induced during in Vitro Monocyte/Macrophage Differentiation-To assess the levels of CD44 proteoglycan expression by naive and "activated" hemopoietic cells, we compared resting human peripheral blood monocytes and T-cells with MDMs and mitogen-stimulated T-cells by flow cytometry using mAbs to the v3 exon which encodes an SGSG motif for HS modification (17) . As shown by the results in Fig. 1A , peripheral blood monocytes and T-cells displayed little if any expression of CD44v3 isoforms. However, MDMs which have features of both activated and differentiated macrophages including elevated HLA-DR histocompatibility antigen and IgG Fc receptors (not shown) expressed significant CD44 v3 levels. This culture-induced expression was also clear from parallel two-color FACS analyses which confirmed the v3 expressing population as CD14 ϩve monocytes (Fig. 1B) . In contrast, mitogen (phytohemagglutinin) stimulated T-cells displayed levels of CD44v3 that were only marginally above background (Fig. 1B and data not shown). This failure to induce CD44 v3 on T-cells was also observed after stimulation with mAbs to the CD3⅐T-cell receptor complex, even though activation was in each case confirmed by elevated IL-2 receptor ␣ chain (CD25) expression (Fig. 1B  and data not shown) . No significant expression of CD44 HSPGs was detected on human B-cells (data not shown).
Analysis of the time course for CD44 v3 expression by MDMs (Fig. 1C) revealed that induction was initiated within the first 12 h of culture and expression sustained for at least a further 84 h. This same prolonged expression pattern was also observed for both CD44H (the predominant species reactive with the F.10.44.2 mAb) and CD44v6 (detected with the 8G5 mAb) confirming and extending recent observations reported by other workers (24) . Furthermore, analysis of total CD44 and CD44 v3 RNA in monocytes and MDMs by Northern blotting and RT-PCR (Fig. 2) indicated the induction of protein expression was paralleled in each case by an increase in the respective mRNA levels. These results suggest that among hemopoietic cells, predominantly macrophages rather than lymphocytes express CD44 proteoglycans and that induction is the result of transcriptional activation. We next characterized the induced CD44v3 polypeptides using cell surface radioiodination and immunoprecipitation. As shown by the results in Fig. 3 , the surface labeling profile of culture-differentiated MDMs revealed a number of high molecular mass bands (110 3 200 kDa) representing splice variants and/or multiple glycoforms of CD44, in addition to the major 90-kDa CD44H species. Induction of these high molecular weight isoforms was critically dependent on culture in the presence of autologous human serum and was inhibited by cycloheximide, indicating de novo synthesis. The induction was also dependent on the culture of monocytes under adherent conditions, as expression was inhibited when cells were incubated in Teflon-coated dishes or in media containing EDTA (not shown), the latter suggesting a possible role for divalent cation (integrin)-mediated adhesion. Immune precipitation with v3 exon-specific mAbs identified 2-3 prominent bands within a "smear" extending above 200 kDa, likely corresponding to CD44 proteoglycan isoforms and their unmodified core proteins (Fig. 3A) . Intriguingly, an almost identical profile was seen in the squamous lung carcinoma cell line "HOTZ" (Fig. 3B) , which express abundant amounts of large (Ͼ200 kDa) CD44 HSPG isoforms in common with other cells of epithelial origin (17, 36) . These are known from previous studies (36) to constitute mostly CD44v3,8 -10 and CD44v3-10 isoforms. However, characterization of the v3 transcripts in MDMs by RT-PCR and Southern blotting, using primers flanking the splice site between exons 5 and 16 (480 bp), yielded primarily one product of approximately 600 bp, corresponding to a splice variant containing the 126-bp v3 exon alone (Fig. 2) . Such a transcript would be expected to encode a core protein in the range 100 -110 kDa (based on size comparisons with a comprehensive panel of cloned CD44 isoforms, Ref. 17 ) that is considerably smaller than the Ͼ200-kDa species actually observed in our experiments. Interestingly, the same 600-bp CD44v3 transcript appears to predominate in the myelo-monocytic cell lines U-937 and HL-60 following activation with phorbol 12-myristate 13-acetate, and in mitogen-activated T-cells, all of which express barely detectable levels of CD44v3 isoforms at the cell surface (data not shown). These results suggest that transcripts encoding the larger v3-containing isoforms detected in MDMs by immunoprecipitation (most likely CD44v3,8 -10 and CD44v3-10) are rapidly turned over and that transcripts containing the v3 exon alone are not efficiently translated.
Biosynthetic labeling of MDMs with 35 SO 4 followed by SDS-PAGE and autoradiography (Fig. 3C) , revealed the v3-containing isoforms migrate as a heterogeneous smear, characteristic of sulfated proteoglycans. Significantly, the majority of this 35 SO 4 -labeled material was sensitive to digestion with heparinase III rather than chondroitinase ABC indicating the inducible v3-containing isoforms on MDMs are predominantly heparan sulfated.
CD44 HSPG Isoforms Both Bind and Present Growth Factor-We next carried out quantitative ligand-binding analyses
to determine the affinity of inducible macrophage CD44 HSPGs for macrophage-derived growth factors and chemokines. Because of the fact MDMs express high levels of another HSPG, syndecan-2, that might complicate the interpretation of such analyses, we instead transfected the relevant CD44 isoforms (CD44 v3-10 and v3,8 -10) into a heterologous, cell surface HSPG negative cell line, the B-lymphoma Namalwa. Analyses with 125 I-labeled growth factors (Fig. 4) confirmed heparinmediated binding to the angiogenic factor FGF-2 and the smooth muscle growth factor hbEGF and in addition revealed binding to VEGF. Interestingly, the binding affinity for FGF-2 (45 nM) was almost an order of magnitude higher than for both VEGF and hbEGF (330 nM).
To determine whether the CD44v3 HSPG isoforms bound FGF-2 in biologically active form we assayed the capacity of CD44v3-10 and v3,8 -10 transfected lymphoma cells to stimulate FGF-mediated proliferation of FGFR1-transfected BaF32 cells, which lack endogenous HSPGs (35) . The results of these assays (Fig. 5) show both the CD44v3,8 -10 and v3-10 HSPG isoforms indeed stimulate FGF-dependent BaF32 cell proliferation. The degree of stimulation was found to be similar to that produced by other well defined cell surface HSPGs including syndecan-1, syndecan-2, syndecan-4, and the glycosylphosphatidylinositol-linked glypican-1. Furthermore, the capacity of the CD44 HSPGs to augment BaF cell proliferation was found to be critically dependent on the integrity of the covalently linked HS chains as no proliferation was observed using HS Ϫve CD44 HSPG isoforms in which the SGSG motif for glycosaminoglycan modification was disrupted by site-directed mutagenesis (Fig. 5) . These results provide the first evidence that CD44 HSPGs on leukocytes not only bind but can positively regulate the activity of FGF-2.
CD44 HSPGs and Chemokine Binding-We next investigated the capacity of CD44v3,8 -10 transfected Namalwa cells to bind a range of C-C chemokines including MIP-1␤ previously reported to be a ligand for CD44 on vascular endothelial cells FIG. 3 . Characterization of CD44 HSPGs induced on monocyte-derived macrophages. CD44 HSPG isoforms induced on culture-differentiated MDM were surface 125 I-radioiodinated or biosynthetically labeled with 35 SO 4 prior to immunoprecipitation and analysis by SDS-PAGE (see "Experimental Procedures"). In panel A, fresh monocytes (M) and 24 h culture monocyte-derived macrophages (MDM) incubated with or without cycloheximide (CHX) were surface iodinated and subjected to immunoprecipitation with either a pan-specific CD44 mAb (total CD44) or with v3 or v6 exon-specific mAbs as shown. In panel B, surface iodinated MDMs and HOTZ squamous cell lung carcinoma (SCC) were subjected to immunoprecipitation with control isotype matched mAb (Con), pan-specific CD44 mAb, CD44 v3 exon-or CD44 v6 exon-specific mAbs. In panel C, CD44 proteoglycan isoforms induced on MDM biosynthetically labeled with 35 SO 4 during cultureinduced differentiation were immunoprecipitated with a v3 exon-specific mAb and cleaved with glycosaminoglycan-digesting enzymes to identify the predominant chain type. Samples electrophoresed are duplicates of immune precipitates incubated either in buffer alone (Con) or in the presence of chondroitin sulfate ABC lyase (CS) or heparan sulfate lyase III (HS) as described under "Experimental Procedures." The positions of the molecular mass calibration markers myosin (205 kDa), ␤-galactosidase (116 kDa), phosphorylase b (97 kDa), and bovine serum albumin (68 kDa) are shown to the right in each case. CD44 HSPGs on MDMs Are Induced by Proinflammatory Cytokines-We next assessed the induction of macrophage CD44 HSPGs by proinflammatory cytokines in view of the fact these agents stimulate synthesis of FGF-2 and other heparinbinding growth factors in these cells (31) . The results of cytokine-activation experiments (Fig. 7) indicated that both IL-1␣, and bacterial lipopolysaccharide promote a 2-3-fold transient increase in CD44v3 levels as assessed by FACS analysis. In contrast, little or no induction was seen with TNF-␣ or with interferon ␥. Among other agents tested, IL-2, IL-4, and granulocyte macrophage-colony stimulating factor all induced small but significant increases in CD44 HSPG levels. However, these were not studied further as the extent of induction varied between monocyte preparations. These results clearly suggest a link between inflammation and macrophage CD44 HSPG expression.
CD44 HSPGs Are Expressed on Macrophages in Inflamed Synovial
Tissue-The induction of CD44 HSPG isoforms during monocyte differentiation and its modulation by pro-inflammatory cytokines led us to search for similar expression on macrophage populations in vivo. Immunohistochemical staining of normal hemopoietic tissues including spleen, tonsil, and peripheral lymph node, however, failed to detect significant expression of CD44 v3 isoforms in these cells (data not shown) and revealed only the well documented expression on epithelial cells (5) .
We next looked for expression on activated macrophages in inflamed tissues. To accomplish this we stained the inflamed synovial membrane from joints affected by rheumatoid arthritis, an autoimmune disease in which the expression of CD44 on both macrophages and other resident synovial cell populations is known to be significantly elevated (11, 12, 38) . As a control, parallel staining was carried out on synovial membrane tissue from non-inflamed joints affected by osteoarthritis, a degenerative disease with a much smaller inflammatory component. Comparison of rheumatoid and osteoarthritic tissue sections revealed a dramatic difference in the level of CD44 v3 expression (Fig. 8) . Whereas CD44 HSPG isoforms were massively up-regulated within the synovial membrane and subintima in rheumatoid tissue, only very low expression was seen in osteoarthritic tissue despite the presence of large numbers of macrophage-like synovial cells (Fig. 8, panels 1, 9, and 10) . In the inflamed rheumatoid synovium, staining for CD44 v3 was largely excluded from the large extralymphoid follicles that contain proliferating T-and B-cells, (Fig. 8, panel 1) confirming the low expression of CD44 HSPGs observed on these cells in vitro (see above). This pattern contrasted markedly with that of the pan-specific CD44 mAb F.10.44.2 which detected abundant levels of CD44 on cells within both the follicles and the membrane/subintima (Fig. 8, panel 2) . Comparative staining of parallel sections using lineage-specific antibodies including CD14, CD68, and CD163 (which, respectively, detect blood-derived macrophages, type A macrophage-like synovial cells and tissue macrophages (28) within the synovial membrane and the subintima) and with vs38 (29) and VCAM-1 (which, respectively, detect plasma cells and fibroblast-like synovial cells) yielded similar patterns to that of CD44 v3 (Fig. 8, panels 3-6) . In contrast, antibodies to CD3 (T-cells) and CD19 (B-cells) clearly stained only within the follicles themselves (Fig. 8, panels 7  and 8) . These results show for the first time that CD44 HSPG isoforms are overexpressed in rheumatoid arthritic synovial membrane and indicate the CD44v3 ϩve cells are largely macrophages and fibroblast-like synovial cells rather than lymphocytes.
To identify the CD44 HSPG ϩve cells more definitively we carried out double-immunofluorescence staining of synovial sections with FITC-labeled CD44v3 mAb and a panel of Texas Red-conjugated lineage-specific mAbs. The results confirmed the majority of CD44 HSPG ϩve cells within the membrane and subintima as immigrant (CD14 ϩve ) or resident (CD163 ϩve ) macrophages (Fig. 9, panel D) . In addition, small numbers of fibroblast-like (VCAM-1 ϩve ) synovial membrane cells also expressed CD44 HSPGs although these were restricted largely to the synovial membrane itself (Fig. 9, panel C) . By comparison, few if any cells double stained with the T-cell (CD3) or plasma cell marker mAbs (Fig. 9, panels A and B) .
Finally, we carried out double immunofluorescence staining to determine if the expression of CD44 HSPGs was co-incident with that of FGF-2. As shown in Fig. 9, section 2 , high levels of FGF-2 were detected in a discrete population of cells within the subintima that expressed abundant levels of CD44 v3 isoforms. To our knowledge, this represents the first co-localization of CD44 HSPG with a heparin-binding growth factor in human tissue. In summary our results confirm expression of CD44 HSPG isoforms is inducible on monocytes both in vivo as well as in vitro and provide further evidence these isoforms may regulate FGF action during inflammation.
DISCUSSION
In this article we have investigated the expression and likely function of HSPG isoforms of the CD44 HA receptor in primary human macrophages. These cells which differentiate from peripheral blood monocytes play key roles in regulating tissue repair and re-modeling during wound healing and inflammation, and have been implicated in the regulation of tumor angiogenesis (39, 40) . These functions are thought to be mediated to a large extent by macrophage-derived growth factors and chemokines, many of which contain binding sites for HS and whose interactions with HSPGs have been well documented (41). Examples include the fibroblast growth factors FGF-1, FGF-2, and VEGF which promote mesenchymal proliferation and angiogenesis by triggering the proliferation of fibroblasts and vascular endothelium (42, 43) . However, the mechanisms by which macrophages regulate the bioavailability of potent heparin-binding growth factors at appropriate times and in the appropriate tissue locations are not well understood. The results which we have presented in this study provide substantial evidence that HSPG isoforms of CD44 with the capacity to bind such factors are induced on differentiated and cytokine-activated macrophages both in vitro and in vivo and can augment productive binding of FGF-2 to the signaltransducing receptor FGFR1 on adjacent cells. Such findings suggest macrophages may utilize CD44 HSPGs for the paracrine regulation of growth factor action.
Using flow cytometric analyses to detect the alternative v3 exon which encodes the motif SGSG for O-glycosylation with HS or CS, we showed that CD44 HSPG isoforms are induced within the first 24 h during differentiation of peripheral blood monocytes to macrophage-like cells. In contrast, we detected little or no CD44 HSPG expression on resting or mitogen (phytohemagglutinin)-activated T-cells or on mitogen-activated Bcells (data not shown). While others have reported isoforms containing the v6 exon are up-regulated upon T-cell activation (6 -8), we have consistently found the extent of induction to be small, i.e. less than 2-fold as detected by standard immunofluorescent antibody staining and flow cytometry (44) . In macrophages, culture-induced differentiation increased CD44 HSPG expression by more than 5-fold, by a mechanism involving de novo RNA and protein synthesis rather than the mobilization of intracellular stores. In addition, a further 2-3-fold increase in CD44 HSPG expression was induced by the proinflammatory cytokine IL-1␣ and bacterial lipopolysaccharide. To our knowledge this is the first demonstration that these agents induce CD44 isoform expression in macrophages. Just recently, however, IL-1 was reported to induce CD44 expression in both vascular smooth muscle (45) and vascular endothelial cells (10) , via a transcriptional mechanism critically dependent on an Egr-1 responsive element upstream of the CD44 promoter (10) . It is interesting to note that IL-1 treatment also increases the HA binding affinity of macrophage CD44 (46) and furthermore, that IL-1 can up-regulate synthesis of HA on vascular endothelial cells (47) . Based upon these and other observations (see below for futher discussion) it has been postulated that interactions between CD44 on monocytes and HA on inflamed endothelia are critical for extravasation at the sites of tissue inflammation (47) . In the light of our own results, it is highly likely that extravasating monocyte/macrophages also up-regulate expression of CD44 HSPGs and that these isoforms play a role in macrophage functions within inflamed tissue.
Consistent with the properties of HSPGs in other cell types (41), we found the CD44 HSPG isoforms induced in macrophages could sequester heparin-binding growth factors with intermediate affinity. Using radioligand-binding analyses we measured apparent K d values of 45 and 330 nM, respectively, for FGF-2, VEGF and hbEGF. These studies represent the first quantitative analyses of CD44-growth factor interactions and both extend and corroborate earlier semiquantitative analyses with Fc fusion proteins expressed in monkey fibroblasts (18) . Moreover, we showed CD44 HSPGs could augment FGF-stimulated proliferation of BaF cells expressing FGFR1, indicating these proteoglycans can present growth factor in biologically active form. Although these results were obtained using transfected lymphoid cells in which the fine structure of HS may differ from that of MDMs, it is very likely that CD44 HSPGs in primary macrophages share the same properties. Such an argument is supported by the fact that syndecan-2 HS chains display comparable binding and presentation of FGF-2 when the core protein is expressed either in transfected Namalwa cells or in primary macrophages (31) . Our results are therefore consistent with a model in which inflammatory macrophages sequester endogenous or locally synthesized heparin-binding growth factors using coordinately induced cell surface HSPGs for the paracrine regulation of tissue growth.
In contrast to growth factors, our studies revealed CD44 HSPGs had little or no affinity for heparin-binding chemokines. Although we surveyed only the C-C chemokines MCP-1, RANTES, and MIP-1␤, additional experiments have also indicated little or no binding to the CXC chemokine IL-8. These findings conflict with an earlier report demonstrating that CD44 isolated from peripheral blood monocytes could immobilize MIP-1␤ and trigger integrin-mediated T-cell adhesion (25) . Furthermore, this discrepancy cannot be explained by the fact our binding assays with CD44 HSPGs were conducted using B-lymphoma transfectants in which the pattern of HS sulfation may differ from that of macrophages, as intact MDMs also failed to display HS-mediated chemokine binding (data not shown). A likely explanation is that the HS chains on MDMs and B-lymphoma cells lack the appropriate sugar sulfation for chemokine binding. This is supported by recent evidence indicating that MIP-1␤ has appreciable affinity only for highly sulfated HS chains (48) .
The various characteristics of macrophage CD44 HSPG expression reported here are strikingly similar to those observed for syndecan-2 (31), a member of the larger syndecan family of HSPGs normally expressed on fibrobasts and endothelial cells (49, 50) . Like CD44, syndecan-2 is specifically up-regulated on macrophages, following in vitro differentiation and activation with IL-1 and lipopolysaccharide (31) . In addition, syndecan-2 on macrophages augments binding of FGF-2 to the signal transducing receptor FGFR1 on neighboring cells but does not engage in heparin-dependent chemokine binding. While these properties predict the functions of both syndecan-2 and CD44 HSPGs on macrophages are likely to overlap, others suggest they may have subtle but significant differences. First, each HSPG is likely to be segregated within a different functional domain of the plasma membrane. CD44 molecules inhabit free surface domains and interact with ERM (Ezrin, Radixin, and Moesin) proteins that cross-link actin filaments to the plasma membrane and organize the formation of microvilli (51) . In contrast, syndecan-2 molecules interact with PDZ domain proteins and are implicated in the formation of plasma membraneextracellular matrix signaling complexes involving growth factor receptors, cytoskeletal actin, and membrane-associated guanylate kinases (52, 53) . Second, the two HSPGs differ in size. CD44 HSPG core proteins are composed mostly of mucinlike sequences and the ectodomains can exceed 600 residues in length, while the syndecan-2 ectodomain is only 127 residues long. These differences in dimensions predict the HS chains extend different distances from the surface of the lipid bilayer, and this could in turn result in differences in their capacity to present growth factor to the appropriate receptors through geometric constraints.
The physiological significance of CD44 HSPG expression on MDMs is underlined by our finding that these HSPGs are also up-regulated in vivo on tissue macrophages within the inflamed synovial membrane in rheumatoid arthritis. Previous studies by other groups have revealed that CD44H is abundantly expressed on synovial fibroblasts, lymphocytes, and macrophages from rheumatoid compared with non-inflamed (osteo-arthritic) synovium (11, 12, 38) and that CD44 isoforms containing v6 and v9 are induced on synovial membrane fibroblasts (54), multinucleated "giant cells" or monocyte polykaryons in RA and in various granulomatous inflammatory diseases (24) . Furthermore, the importance of CD44 in the recruitment of leukocytes from the circulation and in the maintenance of inflammation in RA has been highlighted by the recent demonstration that mAbs which induce surface shedding of CD44 block leukocyte infiltration and joint swelling in mouse models of rheumatoid arthritis (13, 14, 55) . In this present study we have shown using a combination of immunohistochemical staining and immunofluorescence microscopy that macrophages both within and beneath the synovial membrane express CD44 HSPGs while B-and T-cells display little if any expression. The inflammatory response within the rheumatoid synovium is thought to be sustained by the production of proinflammatory cytokines such as IL-1 and TNF-␣ which in turn induce the production of heparin-binding growth factors such as FGF, VEGF, and PDGF that promote synovial fibroblast proliferation and angiogenesis (56, 57) . Monocytes and macrophages are a likely source of these growth factors since they not only synthesize FGF-2 in response to both IL-1 and TNF but also express the HSPGs syndecan-2 and CD44 that can regulate FGF action (31). Hence we speculate that CD44 HSPGs and/or syndecan-2 on synovial membrane and subintimal macrophages are involved in the pathogenesis of inflammatory arthritis. Should this prove to be the case, then a blockade of glycosaminoglycan-mediated interactions involving CD44 or other cell surface HSPGs will be a useful strategy for antiinflammatory drug design.
